Athyrium Provides Capital to Support Long-Term Growth and Exchanges Outstanding Debt into Equity of Certain Reorganized Entities RVL Pharmaceuticals plc Ordinary Shares Expected to be Cancelled in...
Lender to Provide Incremental Liquidity to Support Long-Term Growth Senior Secured Lender to Exchange Outstanding Debt into Equity of the Reorganized Entities Business Operations at U.S....
BRIDGEWATER, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (RVL or the Company), a specialty pharmaceutical company, today announced that Brian Markison, Chief...
BRIDGEWATER, N.J., Aug. 16, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (RVL or the Company), a specialty pharmaceutical company focused on the commercialization of UPNEEQ®...
-- UPNEEQ® remains a significant potential value driver given its rapid early acceptance by providers, large total addressable market and untapped consumer opportunity -- -- Executed financing...
BRIDGEWATER, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (€œRVL€ or the €œCompany€), a specialty pharmaceutical company focused on the commercialization of UPNEEQ®...
BRIDGEWATER, N.J., July 05, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company organized in Ireland focused on the...
BRIDGEWATER, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (RVL or the Company), a specialty pharmaceutical company, today announced results of the proposal to...
-- First quarter 2023 UPNEEQ® net product sales grew 49%, or $2.9 million, over the prior year period to $8.8 million -- -- Enhanced operating leverage with a 32%, or $7.9 million, reduction in...
BRIDGEWATER, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (œRVL or the œCompany), a specialty pharmaceutical company focused on the commercialization of UPNEEQ®...